{}
Our News
Scaling with Purpose: Alnylam Publishes 2025 Corporate Responsibility Report
May 19, 2026
The publication of our 6th corporate responsibility report reflects the growth of our business and the accelerating trajectory of our company. We recognize that with these achievements comes increased expectations about our commitments and transparency.
As we enter this next phase of growth, we continue to evolve our approach to corporate responsibility (CR) by strengthening the systems, governance, and practices that underpin our efforts and deepening our commitments to patients, communities, employees, and the environment.
As we look to the future, our ambition is clear: to deliver life-changing medicines to millions of patients while operating with integrity, discipline, and accountability. Our Corporate Responsibility work is essential to achieving this ambition.” – Yvonne Greenstreet, MD, MBA, OBE, Alnylam CEO
Reflected throughout our report is our global theme, “Accepting Challenges to Improve the Health of Humanity,” which remains central to our strategy and is embedded across interconnected pillars that guide our work — Patients, Science, Employees, Communities, Environment & Operations, and Governance & Integrity.
Expanded investments in patient access support, including the launch of a new Patient Advisory Council and a near doubling in size of the Case Management and Access & Reimbursement teams
Highlights from this year's Alnylam Corporate Responsibility Report include:
-
Expanded investments in patient access support, including the launch of a new Patient Advisory Council and a near doubling in size of the Case Management and Access & Reimbursement teams
-
Published annual patient access metrics, demonstrating strong outcomes in 2025, including $0 out-of-pocket costs for a majority of patients and coverage for more than 95% of U.S. residents across payer types
-
Committed a two-year, $2 million philanthropic investment through Alnylam Challengers to support frontline Care Navigators in underserved communities in Boston
-
Developed a Scope 1 and Scope 2 greenhouse gas (GHG) emission reduction framework through 2030, supported by an independent third-party assessment of the company's underlying GHG inventory and methodology
-
Expanded climate-related reporting, including CDP (Carbon Disclosure Project) submission and voluntary submission in response to California’s Senate Bill 261 (Climate-Related Financial Risk Act)
-
Invested in sustainable drug manufacturing operations, including expansion of Alnylam’s Norton, Massachusetts (US) facility and advancement of next-generation manufacturing technologies, including the siRELIS™ enzymatic ligation platform
-
Completed our first CR double materiality assessment to identify and prioritize the most significant issues for our business and stakeholders, strengthening alignment with leading global frameworks and helping to guide our CR strategy
-
Advanced our diversity and inclusion strategy, with 90% of employees affirming in our annual culture survey that Alnylam supports a diverse workplace (an increase from our 2024 survey score)
-
Shared case studies that demonstrate our strategic investments as we grow across patient access and support, clinical trials, employee resource networks, philanthropy, product quality and safety, manufacturing and artificial intelligence
-
Received more than 30+ top workplace awards globally, with the company receiving Great Place to Work awards in 10 countries in 2025
- Earned recognition for our CR efforts with inclusion in Newsweek’s “Most Responsible Companies” and the HumanKind 100 lists for the 4th year in a row
We are proud of the progress made in 2025 and remain grateful to our employees and external partners whose collaboration and commitment continue to drive our CR efforts forward.
The full 2025 Alnylam Corporate Responsibility Report is now available and provides additional detail on the company’s progress and priorities for the year ahead.
Alnylam Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding Alnylam’s corporate responsibility strategy and ambition; the company’s plans to strengthen the systems, governance and practices that underpin its corporate responsibility efforts and to deepen its commitments to patients, communities, employees and the environment; Alnylam’s Scope 1 and Scope 2 greenhouse gas emission reduction framework through 2030 and its expected emissions trajectory; planned investments in sustainable drug manufacturing operations, including the expansion of Alnylam’s Norton, Massachusetts facility and the advancement of next-generation manufacturing technologies, including the siRELIS™ enzymatic ligation platform; and the company’s ability to deliver life-changing medicines to millions of patients while operating with integrity, discipline and accountability, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to the company’s ability to design, implement and achieve its corporate responsibility, sustainability and climate-related goals and commitments on the timelines and in the manner currently anticipated; the evolving legal, regulatory and policy landscape applicable to climate-related and other corporate responsibility disclosures; the availability and reliability of data, methodologies and third-party assessments used in connection with such disclosures; the ability to execute on planned investments in manufacturing, philanthropy and community initiatives; and those risks, uncertainties and other factors more fully discussed in Alnylam’s most recent Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
FOLLOW US
